Nasdaq Grants SpiSparc, Ltd. Extension To Maintain Listing: +600% Bid Price Surge Needed
Portfolio Pulse from Lara Goldstein
Clinical-stage biopharma company SciSparc Ltd. (NASDAQ:SPRC) has been granted an additional 180-day compliance period by Nasdaq to regain compliance with the stock market’s minimum bid price rule. The company's shares need to surge over 600% to meet the $1.00 minimum bid price. SciSparc is engaged in several drug development programs based on THC and/or non-psychoactive CBD. The company also owns a controlling interest in a company selling hemp seeds oil-based products on Amazon (NASDAQ:AMZN). Clearmind Medicine (NASDAQ:CMND) has also recently entered its first Nasdaq compliance period.
September 07, 2023 | 7:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
SciSparc has been granted an extension by Nasdaq to regain compliance with the minimum bid price rule. The company's shares need to surge over 600% to meet the requirement.
The news of the extension granted by Nasdaq is directly related to SciSparc. The company's shares need to surge significantly to meet the minimum bid price rule, which could potentially impact the stock negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
SciSparc owns a controlling interest in a company selling hemp seeds oil-based products on Amazon.
While SciSparc's business interest on Amazon is mentioned, it's not the main focus of the news and is unlikely to have a significant impact on Amazon's stock.
CONFIDENCE 80
IMPORTANCE 30
RELEVANCE 50
NEUTRAL IMPACT
Clearmind Medicine has recently entered its first Nasdaq compliance period.
The news mentions Clearmind Medicine's entry into its first Nasdaq compliance period, but it's not the main focus of the news and is unlikely to have a significant impact on Clearmind's stock.
CONFIDENCE 80
IMPORTANCE 30
RELEVANCE 50